SCHEMBL6947716

SCHEMBL6947716

ClCCCN(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
NCOR2 Q9Y618 2/20 0.50
BCHE P06276 1/20 0.46
OPRM1 P35372 4/20 0.46
ALDH1A1 P00352 3/20 0.46
TSHR P16473 3/20 0.46
OPRD1 P41143 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
CHRM2 P08172 2/20 0.46
HTR1A P08908 2/20 0.46
ADRA2A P08913 2/20 0.46
CHRM1 P11229 2/20 0.46
DRD1 P21728 2/20 0.46
SLC6A2 P23975 2/20 0.46
ADRA1A P35348 2/20 0.46
DRD3 P35462 2/20 0.46
SLC6A3 Q01959 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1593455 0.98 HDAC3 (0.49) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL9704934 0.98 BCHE (0.47) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL29151407 0.94 OPRM1 (0.49) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL6947911 0.94 HDAC3 (0.53) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL6944690 0.92 HDAC3 (0.54) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL11194497 0.88 KCNH2 (0.56) BCHEOPRM1CHRM2HTR1AADRA2A
SCHEMBL479112 0.86 OPRM1 (0.47) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL11795941 0.86 HDAC3 (0.56) HDAC3HDAC1HDAC2HDAC8NCOR2
SCHEMBL4974601 0.86 HDAC3 (0.61) HDAC3HDAC1HDAC2HDAC8NCOR2
Hydrochloric Acid SCHEMBL334991 0.84 OPRM1 (0.49) HDAC3HDAC1HDAC2HDAC8NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0407032-B1 Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia WYETH JOHN & BROTHER LTD (GB) 1994-11-09 EP claimed
US-5086073-A Brain disorders JOHN WYETH & BROTHER LIMITED (GB) 1992-02-04 US claimed
EP-0407032-A2 Aromatic and heteroaromatic amines for treating depressions, cerebral insufficiency disorders or dementia JOHN WYETH & BROTHER LIMITED (GB) 1991-01-09 EP claimed
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS INC (US) 2026-04-30 US disclosed
WO-2025081019-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE IAMBIC THERAPEUTICS, INC. (US) 2025-04-17 WO disclosed
WO-2021118906-A1 PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE ELI LILLY AND COMPANY (US) 2021-06-17 WO disclosed
US-9463262-B2 Cell adhesive material for biological tissue SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2016-10-11 US disclosed
US-20130289254-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE SANYO CHEMICAL INDUSTRIES, LTD. (JP) 2013-10-31 US disclosed
EP-2636415-A1 CELL ADHESIVE MATERIAL FOR BIOLOGICAL TISSUE Sanyo Chemical Industries, Ltd. (JP) 2013-09-11 EP disclosed
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-4363814-A VASODILATORS AND CNS STIMULANTS BOEHRINGER INGELHEIM GMBH (DE) 1982-12-14 US disclosed
US-4343800-A ANTIDEPRESSANTS; ADRENERGIC BLOCKING, HYPOTENSIVE, AND ANTIARRHYTHMIA AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1982-08-10 US disclosed
US-4296117-A ADRENERGIC BLOCKING AGENTS, ANTIDEPRESSANTS BOEHRINGER INGELHEIM GMBH (DE) 1981-10-20 US disclosed
US-4271158-A Vasodilating or antidepressant phenalkanolaminoalkyl-substituted imidazolidinones BOEHRINGER INGELHEIM GMBH (US) 1981-06-02 US disclosed
US-4256756-A ADRENERGIC BLOCKING AGENTS, ANTIDEPRESSANTS BOEHRINGER INGELHEIM GMBH (DE) 1981-03-17 US disclosed
US-4255430-A ANDRENERGIC RECEPTOR BLOCKING AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1981-03-10 US disclosed
US-4215119-A VASODILATORS, ANTIDEPRESSANTS BOEHRINGER INGELHEIM GMBH (DE) 1980-07-29 US disclosed
US-4212877-A ANTIDEPRESSANTS, ADRENERGIC BLOCKING AGENTS BOEHRINGER INGELHEIM GMBH (DE) 1980-07-15 US disclosed
US-4154829-A ANTIDEPRESSANT, VASODILATION BOEHRINGER INGELHEIM GMBH (DE) 1979-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116881-A1 KIF MODULATOR COMPOUNDS AND METHODS OF USE KIF2C, KIF5B, KIF5C HDAC3 243/4885HDAC1 281/4885HDAC2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.